US-based biopharmaceutical company Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948, a BTK degrader designed to treat relapsed/refractory Waldenstrom's macroglobulinaemia (WM).

The findings were shared at the 12th International Workshop on Waldenstrom's Macroglobulinemia in Prague, Czech Republic, which was held from 17 to 19 October.

WM is a rare non-Hodgkin's lymphoma marked by abnormal lymphocytes and monoclonal immunoglobulin M (IgM) production.

As of 17 April, the trial data showed NX-5948's safety across all dosages from 50mg to 600mg administered orally daily.

In the trial, the therapy showed objective response in seven out of nine evaluable patients (77.8%), with two patients showing stable disease.

Seven responses were recorded at the first eight-week assessment, while five patients are still undergoing treatment, with two of these patients having been treated for more than a year.

Nurix chief medical officer Paula O'Connor said: "We are encouraged by the emerging positive data from NX-5948 in patients with Waldenstrom's macroglobulinemia, which add to the previously disclosed robust clinical activity observed in patients with chronic lymphocytic leukaemia.

"These data support our decision to advance NX-5948 into the ongoing Phase 1b expansion cohort in patients who have previously received at least one prior line of therapy including a BTK inhibitor and patients presenting with Bing-Neel syndrome, a rare form of WM with central nervous system involvement where NX-5948's ability to penetrate the brain may offer a distinct advantage."

Further data from 10 October included details on the first 13 WM subjects enrolled in both the Phase Ia and Ib stages of the trial.

These patients had a median age of 74 and had undergone an average of three previous therapies, including BTK inhibitors and chemo-immunotherapy.

Based in California, Nurix Therapeutics focuses on developing and commercialising therapies for cancer, inflammatory conditions and other diseases.

"Nurix Therapeutics' NX-5948 shows promise in Waldenstrom's macroglobulinaemia trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.